El propósito del estudio es determinar si benralizumab reduce la tasa de exacerbaciones de EPOC en pacientes sintomáticos con EPOC moderada a muy grave que reciben terapias de tratamiento estándar.

Elegibilidad

Edad mínima: 40 YearsEdad máxima: 85 YearsSexo: ALL

Criterios de inclusión

Informed consent.
Subjects 40-85 y.o.
Moderate to very severe COPD with Post Bronchodilator (BD) FEV1\>20% and ≤65%.
≥2 moderate or ≥1 severe COPD exacerbation(s) required treatment or hospitalization within 2-52 weeks prior to Visit1.
Modified Medical Research Council (mMRC) score ≥1 at Visit 1.
Treatment with double or triple therapy throughout the year prior to Visit 1, constant 2 weeks prior to Visit 1.
Tobacco history of ≥10 pack-years.
Women of childbearing potential must use a highly effective form of birth control from Visit 1 until 16 weeks after their last dose, and negative serum pregnancy test result at Visit 1.
Male subjects who are sexually active must be surgically sterile one year prior to Visit 1 or use an adequate method of contraception from the first Investigational Product (IP) dose until 16 weeks after their last dose.
Compliance with maintenance therapy during run-in ≥70%.
Blood eosinophils due to subject's stratification and cap for blood eosinophil levels.When any eosinophil cohort is full, subjects in the completed cohort will not be randomised and will be withdrawn from the study.

Criterios de exclusión

Clinically important pulmonary disease other than COPD or another diagnosed pulmonary or systemic disease associated with elevated peripheral eosinophil counts.
Any disorder or major physical impairment that is not stable by Investigator opinion and/or could affect: - subject safety-study findings or their interpretation or subject's ability to complete the entire study duration.
Unstable ischemic heart disease, arrhythmia, cardiomyopathy, or other relevant cardiovascular disorder that in Investigator's judgment may put the patient at risk or negatively affect the study outcome.
Treatment with systemic corticosteroids and/or antibiotics, and/or hospitalization for a COPD exacerbation within 2 weeks prior to Visit1 or during the enrolment and run-in period.
Acute upper or lower respiratory infection requiring antibiotics within 2 weeks prior to Visit1 or during the enrolment and run-in period.
Pneumonia within 8 weeks prior to Visit1 or during the enrolment and run-in period.
Pregnant, breastfeeding, or lactating women.
Risk factors for pneumonia
History of anaphylaxis to any other biologic therapy.
Long term oxygen therapy with signs and/or symptoms of cor pulmonale, right ventricular failure.
Use of immunosuppressive medication within 2 weeks prior to Visit1 and/or during the enrolment and run-in period.
Receipt of any investigational non-biologic product within 30 days or 5 half-lives prior to Visit 1.
Evidence of active tuberculosis (TB) without an appropriate course of treatment.
Lung volume reduction surgery within the 6 months prior to Visit 1. History of partial or total lung resection (single lobe or segmentectomy is acceptable).
Asthma as a primary or main diagnosis according to the Global Initiative for Asthma (GINA) guidelines or other accepted guidelines.
Previous treatment with benralizumab.
Helminth parasitic infection diagnosed within 24 weeks prior to Visit 1.

Intervenciones

drug

Benralizumab Arm A

Benralizumab subcutaneously on study week 0 until study week 48 inclusive

drug

Benralizumab Arm B

Benralizumab subcutaneously on study week 0 until study week 48 inclusive

drug

Benralizumab Arm C

Benralizumab subcutaneously on study week 0 until study week 48 inclusive

drug

Placebo

Benralizumab subcutaneously on study week 0 until study week 48 inclusive

Ubicaciones

Research Site

Buenos Aires, Argentina

Research Site

CABA, Argentina

Research Site

CABA, Argentina

Research Site

CABA, Argentina

Research Site

CABA, Argentina

Research Site

Ciudad Autónoma de Buenos Aire, Argentina

Research Site

Ciudad de Buenos Aires, Argentina

Research Site

Concepción del Uruguay, Argentina

Research Site

Corrientes, Argentina

Research Site

Córdoba, Argentina

Research Site

Córdoba, Argentina

Research Site

Florida, Argentina

Research Site

Mar del Plata, Argentina

Research Site

Mar del Plata, Argentina

Research Site

Mendoza, Argentina

Research Site

Mendoza, Argentina

Research Site

Nueve de Julio, Argentina

Research Site

Quilmes, Argentina

Research Site

Rosario, Argentina

Research Site

San Fernando, Argentina

Research Site

San Juan Bautista, Argentina

Research Site

San Miguel de Tucumán, Argentina

Estudio de fase 3, aleatorizado, doble ciego, doble simulación, controlado con placebo, multicéntrico, de grupos paralelos, de 56 semanas, que evalúa la eficacia/seguridad de 3 dosis de benralizumab en pacientes con EPOC moderada a muy grave con exacerbaciones previas.

Resumen

Elegibilidad

Criterios de inclusión

Criterios de exclusión

Intervenciones

Benralizumab Arm A

Benralizumab Arm B

Benralizumab Arm C

Placebo

Ubicaciones

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Patrocinadores